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1478Objective: Atrial fibrillation occurs frequently after cardiac surgery and not only prolongs hospitalization but
also influences the prognosis. We investigated whether landiolol hydrochloride, an ultrashort-acting beta-
blocker, could reduce postoperative atrial fibrillation in a randomized controlled trial.
Methods: The subjects were 140 patients undergoing coronary artery bypass grafting at the Nihon University
School of Medicine. The primary end point was occurrence/non-occurrence of atrial fibrillation up to 1 week
postoperatively. Logistic regression analysis was performed to investigate risk factors for atrial fibrillation
among preoperative, perioperative, and postoperative variables.
Results: Atrial fibrillation occurred in 7 patients (10%) in the landiolol group versus 24 patients (34.3%) in the
placebo group; the landiolol group had a significantly lower incidence (P¼ .0006). Postoperative heart rate was
significantly lower in the landiolol group than in the placebo group. On returning to the intensive care unit, the
landiolol group had significantly lower inflammatory and ischemic parameters. Medical costs were also signif-
icantly lower in the landiolol group. Multivariate analysis revealed that significant risk factors for atrial fibril-
lation were a European System for Cardiac Operative Risk Evaluation of 10 or more, preoperative non-use of
angiotensin receptor blockers, and non-use of landiolol.
Conclusions: Postoperative atrial fibrillation was reduced by treatment with landiolol hydrochloride. Ameliora-
tion of ischemia, an anti-inflammatory effect, and inhibition of sympathetic hypertonia by landiolol presumably
reduced the occurrence of atrial fibrillation. Hypotension or bradycardia did not develop in any of the patients, in-
dicating the safety of this beta-blocker. These findings suggest that landiolol hydrochloride could be useful in the
perioperative management of patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2011;141:1478-87)Atrial fibrillation (Af) is a common complication of cardiac
surgery, and its incidence has been variously reported as
16% to 85%.1-5 Postoperative Af prolongs the hospital
stay of patients and influences both early and late
survival,6 so prevention is important. It has been reported
that postoperative Af is associated with advanced age, obe-
sity, preoperative cardiac dysfunction, respiratory failure, re-
nal impairment, inflammation, ischemia–reperfusion injury,
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The Journal of Thoracic and Cardiovascular SurAlthough consensus on the causes has not been achieved,
a close relationship between advanced age and the
occurrence ofAfwas suggested by all the studiesmentioned.
The efficacy of several b-blockers and amiodarone for
prevention of Af has been demonstrated by randomized con-
trolled trials (RCTs).4,10,11 The guidelines of the American
College of Cardiology/American Heart Association
recommend oral b-blocker therapy for patients undergoing
cardiac surgery who have no contraindications to prevent
postoperative Af (class I), and amiodarone is also
recommended for prevention of Af (class IIa) 12). RCTs
have been performed on various drugs to date, but the
results have not been consistent. There are reports of
postoperative AF incidences of less than 10%, including
3% when atenolol was administered orally from
preoperatively13 and 9.8%with postoperative oral adminis-
tration of propranolol,14 but there have also been reports of
incidences of 12.5% to 34% or no differences when drugs
were used.4,10,11,15 Moreover, few RCTs have investigated
prophylactic intravenous administration of b-blockers, and
the efficacy of such drugs has not been proven.
The Prevention of Atrial fibrillation in patientS having
CArdiac surgery with landiolol hydrochloride for coronarygery c June 2011
Abbreviations and Acronyms
ACE-I ¼ angiotensin-converting enzyme
inhibitor
Af ¼ atrial fibrillation
ARB ¼ angiotensin receptor blocker
CABG ¼ coronary artery bypass grafting
CK-MB ¼ creatine kinase isoenzyme MB
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
hs-CRP ¼ highly sensitive C-reactive protein
I-CTP ¼ pyridinoline cross-linked
telopeptide of type I collagen
ICU ¼ intensive care unit
IL ¼ interleukin
KL-6 ¼ sialylated carbohydrate antigen
KL-6
PASCAL ¼ Prevention of Atrial fibrillation in
patientS having CArdiac surgery
with landiolol hydrochloride
RCT ¼ randomized controlled trial
Sezai et al Perioperative Managementartery bypass grafting (CABG) (PASCAL trial for CABG)
was designed to investigate the efficacy of landiolol hydro-
chloride, an ultrashort-acting b1-selective b-blocker, for
prevention of postoperative Af. Landiolol was developed
in Japan and released in 2002. It has a shorter half-life,16
higher b1/b2 selectivity ratio, and weaker negative inotropic
effect compared with other intravenous b-blockers, so the
risk of hypotension is small.16-18 Landiolol has only beenisolated C
(n=16enrollment
allocation
follow-up
analysis
Randomizatio
landiolol group 
(n=71)
Followed-up (n=71)
Analyzed (n=70)
Excluded from analysis due to 
lack of data (n=1)
FIGURE 1. Disposition of the subjects: The PASCAL trial was conducted i
The Journal of Thoracic and Carapproved in Japan at present, and this was the first RCT
investigating its efficacy for postoperative Af.
PATIENTS AND METHODS
Study Protocol
The PASCAL trial for CABGwas a randomized, double-blind, placebo-
controlled study. It was conducted after obtaining approval from the ethics
committee of Nihon University School of Medicine Itabashi Hospital. In-
formed consent was provided by each patient after receiving an explanation
about this study.
The subjects were patients who were scheduled to undergo CABG on
cardiopulmonary bypass. We excluded patients with cardiogenic shock, si-
nus bradycardia (resting heart rate  50/min), second- or third-degree
atrioventricular block, clinical hypothyroidism or hyperthyroidism, a his-
tory of arrhythmia, and those undergoing off-pump surgery. Patients
were randomized into 2 groups by the lotterymethod. Landiolol hydrochlo-
ride (Ono Pharmaceutical Co, Ltd, Osaka, Japan) was administered at the
time of central anastomosis during CABG in the landiolol group or phys-
iologic saline was administered in the placebo group. Patients were treated
in a blinded manner. Landiolol infusion was started at 2 mg/kg/min and dis-
continued after 48 hours. If the heart rate was 90 beats/min or less, right
atrial pacing was performed at a rate of 90 times/min for 48 hours.
CABG was performed with cardiopulmonary bypass (Jostra HL-20, Jostra
Inc, Hirrlingen, Germany) and nonpulsatile perfusion at a tepid tempera-
ture (rectal temperature: 34C) by the intermittent aortic crossclamp
method without cardioplegic solution. In all patients, the left internal
thoracic artery was anastomosed to the left anterior descending coronary
artery, and radial artery or saphenous vein grafts were used for other
vessels.
The pulse rate was monitored to detect Af for 1 week after surgery by
continuous electrocardiographic monitoring. Occurrence of Af was defined
as persistence of this arrhythmia for 5 minutes or more or a requirement for
treatment because of hemodynamic changes. In this study, patients who
had postoperative Af were treated with amiodarone hydrochloride, pilsicai-
nide hydrochloride, or digitalis. The protocol avoided the use of oral
b-blockers as much as possible; they were used only when it was
considered necessary in patients with conditions such as left ventricular
dysfunction.ABG
0)
n (n=142)
Excluded (n=18)
Not meeting inclusion criteria (n=11)
Refusal to enroll (n=7)
placebo group 
(n=71)
Followed-up (n=71)
Analyzed (n=70)
Excluded from analysis due to 
lack of data (n=1)
n 140 patients who underwent isolated coronary arterial bypass grafting.
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TABLE 1. Comparison of clinical characteristics and measured data
Landiolol
group
Placebo
group
P
value
No. 70 70
Age (y) 68.5  4.7 66.7  8.9 .2423
Gender (male: female) 62: 8 66: 4 .3660
Body surface area (m2) 1.69  0.17 1.73  0.17 .1743
euroSCORE 5.2  2.9 5.4  4.1 .7746
Diagnosis .7899
Acute myocardial infarction 6 8
Old myocardial infarction 27 24
Unstable angina 26 27
Stable angina 11 11
Emergency surgery 17 19 .8469
Risk factors
Diabetes mellitus 35 37 .8658
Hypertension 58 50 .1582
Hyperlipidemia 36 42 .3950
Obesity 13 14 1.00
Smoking 32 26 .3911
COPD 3 2 1.00
Cerebrovascular disease 3 3 1.00
Chronic renal failure 12 12 1.00
Oral medications
ARB 39 37 .8654
ACE-I 4 6 .7447
Ca antagonist 24 28 .6000
Beta blocker 17 25 .1964
Aldosterone blocker 6 3 .4932
Statin 19 26 .2775
Ejection fraction (%) 54.5  14.2 55.6  13.5 .6598
sBP (mm Hg) 135.0  18.7 135.3  18.6 .9352
dBP (mm Hg) 76.6  11.2 78.5  12.2 .3496
CVP (mm Hg) 6.4  1.6 6.7  1.6 .3097
Heart rate (beats/min) 74.7  11.7 76.1  10.7 .4518
hs-CRP (mg/dL) 0.76  1.64 0.63  1.25 .6141
IL-6 (pg/mL) 5.7  6.4 5.2  8.1 .8289
IL-8 (pg/mL) 6.5  4.0 5.3  3.8 .7037
CK-MB (U/L) 62.2  48.1 69.3  70.9 .7662
Urinary-OHdG (ng/mg Cr) 11.0  5.1 11.9  6.6 .9350
KL-6 (U/mL) 222.3  89.2 234.7  126.9 .5320
I-CTP (ng/mL) 10.4  12.0 9.1  9.6 .5369
Hyaluronic acid (ng/mL) 58.0  52.9 45.0  41.8 .1427
COPD, Chronic obstructive pulmonary disease; ARB, angiotensin II receptor blocker;
ACE-I, angiotensin-converting enzyme inhibitor; sBP, systolic blood pressure;
dBP, diastolic blood pressure; CVP, central venous pressure; hs-CRP, highly sensitive
C-reactive protein; CK-MB, creatine kinase isoenzyme MB; OHdG, 8-hydroxydeox-
yguanosine; KL-6, sialylated carbohydrate antigen KL-6; I-CTP, pyridinoline
cross-linked telopeptide of type I collagen.
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MThe primary end point was the occurrence/non-occurrence of Af during
the initial 1-week period after surgery. The secondary end points were (1)
operative mortality and complications; (2) hemodynamics (systolic blood
pressure, diastolic blood pressure, heart rate before surgery) at the return
to the intensive care unit (ICU), at 12, 24, and 48 hours after administration,
and at 24 hours after discontinuing administration (in patients on pacing,
the pacemaker was stopped before measuring the heart rate); (3) fluid bal-
ance (during cardiopulmonary bypass and on postoperative days 0–3); (4)
creatine kinase isoenzymeMB (CK-MB) (at the return to ICU, 3 hours after
returning, and on postoperative days 1 and 3), and troponin-I and human1480 The Journal of Thoracic and Cardiovascular Surheart fatty acid-binding protein (at the return to ICU and on postoperative
days 1 and 3) as indices of ischemia–reperfusion injury; (5) interleukin
(IL)-6, IL-8, and highly sensitive C-reactive protein (hs-CRP) as indices
of inflammation (before surgery, at the return to ICU, and on postoperative
days 1, 3, and 7); (6) urinary 8-hydroxydeoxyguanosine as an index of ox-
idative stress (before surgery, on returning to ICU, and on postoperative
days 1, 3, and 7); and (7) the total cost of hospital treatment. Postoperative
complications were categorized as central nervous system disorders, car-
diovascular disorders (low output syndrome), heart failure, perioperative
myocardial infarction (CK-MB of> 5 times the normal level, abnormal
ST segments or Twaves on electrocardiogram, and refractory arrhythmia),
respiratory failure, acute renal failure (requiring dialysis), gastrointestinal
disorders (gastrointestinal bleeding, ileus, or a requirement for high-calorie
alimentation, eg, in patients with liver dysfunction), infections (eg, septice-
mia, pneumonia, mediastinitis), and other disorders requiring long-term
ICU management.
Investigation of Factors Associated With Atrial
Fibrillation
The patients were compared with respect to preoperative, perioperative,
and postoperative factors in relation to the occurrence of postoperative Af.
Preoperative factors investigated age, gender, body surface area, euro-
SCORE, emergency surgery, left ventricular ejection fraction, oral drug
therapy, preoperative hematology and urinalysis parameters, and markers
of fibrosis (sialylated carbohydrate antigen KL-6 [KL-6], pyridinoline
cross-linked telopeptide of type I collagen [I-CTP], and hyaluronic acid).
Perioperative/postoperative factors were landiolol use, aortic crossclamp-
ing time, extracorporeal circulation time, hospital stay (days), and medical
costs.
Logistic regression analysis was also conducted using preoperative
factors (age  70 years, male sex, euroSCORE> 10 points, ejection
fraction< 40%, hs-CRP> 3.0 mg/dL, preoperative oral drug therapy,
KL-6>300 U/mL, hyaluronic acid>80 ng/mL, and I-CTP>10 ng/mL)
and perioperative factors (activated clotting time>40 min, extracorporeal
circulation time> 120 min, landiolol use, and postoperative oral drug
therapy) to investigate associations with Af.
Statistical Analysis
Results are expressed as the mean standard deviation. For parametric
and nonparametric data, the significance of differences was determined
with Student t test and Fisher’s exact test, respectively. Patients with or
without Af were compared for clinical characteristics, preoperative hema-
tology data, perioperative/postoperative parameters, and postoperative he-
matology data using Fisher’s exact test or the unpaired Student t test.
Independent predictors of Af were examined by multivariate analysis using
the parameters detected with univariate analysis. Other data were analyzed
by repeated-measures analysis of variance.RESULTS
Disposition of Patients
The 142 patients registered in the PASCAL trial for
CABG were randomized equally to 2 groups: 71 patients
treated with landiolol (landiolol group) and 71 patients
treated with physiologic saline (placebo group). Adminis-
tration was not discontinued because of hypotension or bra-
dycardia in either group, and all patients completed the
study. However, some postoperative hematology data
were missing in 1 patient each from the landiolol group
and the placebo group, so the remaining 70 patients from
each group were studied (Figure 1).gery c June 2011
TABLE 2. Perioperative and postoperative findings
Landiolol
group
Placebo
group
P
value
No. 70 70
Occurrence of Af 7 (10.0%) 24 (34.3%) .0006
Days until Af 3.4  2.3 2.5  1.2 .1556
Mortality 0 2 .1699
Complications 3 6 .4931
No. of bypasses 3.2  1.0 3.2  0.8 .8549
Surgeon .6965
Surgeon M 34 31
Surgeon H 17 20
Surgeon S 19 19
ACCT (min) 23.4  9.1 23.2  9.3 .9054
ECCT (min) 103.1  28.3 105.0  29.8 .6912
Hospital stay (d) 11.2  4.9 14.0  7.6 .0102
Oral medications
ARB 32 36 .6121
ACE-I 2 3 1.00
Ca antagonist 38 36 .8656
Beta-blocker 14 20 .3245
Aldosterone blocker 53 49 .5689
Statin 43 41 .8631
Ejection fraction (%) 55.2  15.0 55.8  11.6 .7958
Hospital cost $35,679.48 
$6273.40
$39,981.43 
$13,417.62
.0202
Af, Atrial fibrillation; ACCT, aortic crossclamping time; ECCT, extracorporeal
circulation time; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-
converting enzyme inhibitor. FIGURE 3. Changes of blood pressure (systolic blood pressure and dia-
stolic blood pressure [upper]) and heart rate [lower]. Systolic and diastolic
blood pressure showed no significant differences between the 2 groups, but
heart ratewas significantly lower in the landiolol group. sBP, Systolic blood
pressure; dBP, diastolic blood pressure; HR, heart rate.
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As shown in Table 1, the baseline characteristics of the 2
groups showed no differences.P
MPrimary End Point
Postoperative Af occurred in 7 patients (10%) in the
landiolol group versus 24 patients (34.3%) in the placebo
group; the landiolol group showed a significantly lower in-
cidence (P ¼ .0006) (Table 2). Most patients (128/140) re-
ceived pacing at 90 times/min immediately after surgery. In
both the landiolol and placebo groups, 64 patients receivedFIGURE 2. Days of occurrence of Af.
The Journal of Thoracic and Carpacing, and there was no difference between the groups. Af
occurred after 3.4  2.3 days in the landiolol group and 2.5
 1.2 days in the placebo group, showing no significant dif-
ference of onset (P¼ .1556). Among patients with Af, more
than half of the patients contracted Af after discontinuing
administration of landiolol or placebo (5 patients [71.4%]
in the landiolol group and 14 patients [58.3%] in the pla-
cebo group), but no significant differences were foundFIGURE 4. Perioperative and postoperative fluid balance: Fluid balance
showed no statistically significant difference between the 2 groups.
diovascular Surgery c Volume 141, Number 6 1481
FIGURE 5. Ischemia–reperfusion injury parameters: CK-MB on postoperative day 1, troponin-I on postoperative days 1 and 3, and human heart fatty acid-
binding protein on postoperative day 1 (at the time of returning to ICU) were significantly lower in the landiolol group comparedwith the placebo group.CK-
MB, Creatine kinase isoenzyme MB; H-FABP, human heart fatty acid-binding protein.
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(n ¼ 19, 79.2%) was higher on postoperative days 2 to 4,
when patients are reported to be susceptible to postoperative
Af, in the placebo group (n¼ 19, 79.2%) compared with the
landiolol group (n ¼ 3, 42.9%) (P ¼ .1504) (Figure 2).
In this study, b-blockers were administered orally in 34
patients after surgery. Fourteen of these patients were
treated with landiolol and 20 patients were treated with pla-
cebo, and there was no statistically significant difference
between the groups (P ¼ .3245).
Secondary End Points
Operative mortality and complications. There were no
perioperative deaths in the landiolol group versus 2 such
deaths in the placebo group (mediastinitis and cardiac fail-
ure) (P ¼ .1699) (Table 2). Perioperative complications oc-
curred in 3 patients in the landiolol group versus 6 patients
in the placebo group (P¼ .4931). In the landiolol group, the
complications were low output syndrome, acute renal fail-
ure, and cerebral infarction in 1 patient each. In the placebo
group, 2 patients had heart failure, and 1 each had low
output syndrome, refractory arrhythmia, mediastinitis, and
cerebral infarction.
Hemodynamics. No significant differences were observed
between the 2 groups with respect to the preoperative sys-
tolic blood pressure, diastolic blood pressure, and heart
rate (Figure 3). No significant differences were seen with1482 The Journal of Thoracic and Cardiovascular Surrespect to postoperative blood pressure, but the heart rate
was significantly lower in the landiolol group after discon-
tinuation of administration.
Fluid balance. There were no intraoperative or postopera-
tive differences of fluid balance between the 2 groups
(Figure 4).
Parameters of ischemia–reperfusion injury. On postop-
erative day 1, the CK-MB level was 44.5  29.4 U/L in
the landiolol group and 62.5  69.0 U/L in the placebo
group, with the landiolol group having a significantly lower
CK-MB level (P¼ .0463) (Figure 5). Troponin-I was 13.0
12.6 ng/mL in the landiolol group and 18.9  17.1 ng/mL
in the placebo group on postoperative day 1, and 6.7 
10.0 ng/mL and 11.5 13.7 ng/mL, respectively, on postop-
erative day 3. The landiolol group showed significantly
lower values on both day 1 (P ¼ .0226), and day 3
(P ¼ .0365). Human heart fatty acid-binding protein was
77.8  90.0 ng/mL in the landiolol group and 212.9 
547.7 ng/mL in the placebo group at the return to ICU, as
well as 44.8  77.8 ng/mL in the landiolol group and
113.2 281.5 ng/mL in the placebo group on postoperative
day 1. The landiolol group showed lower values (return to
ICU: P ¼ .0472, postoperative day 3: P ¼ .0425).
Inflammatory parameters data. No statistically signifi-
cant differences were observed between the 2 groups with
respect to preoperative hs-CRP, IL-6, and IL-8 levels
(Figures 6 and 7). hs-CRP was significantly lower in thegery c June 2011
FIGURE 6. hs-CRP (upper) and urinary 8-hydroxydeoxyguanosine
(lower). hs-CRP was significantly lower on postoperative day 3 in the land-
iolol group compared with the placebo group, but urinary 8-hydroxydeox-
yguanosine showed no significant difference between the 2 groups.
FIGURE 7. IL-6 (upper) and IL-8 (lower). IL-6 (on postoperative days 1
and 3) and IL-8 (on returning to ICU) were significantly lower in the land-
iolol group than in the placebo group.
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operative day 3 (P ¼ .0070). IL-6 was 22.4  15.7 pg/mL
in the landiolol group and 36.9 36.1 pg/mL in the placebo
group on postoperative day 1, whereas it was 13.7  12.2
pg/mL and 27.3  25.9 pg/mL, respectively, on day 3.
The landiolol group showed significantly lower values com-
pared with the placebo group (postoperative day 1:
P ¼ .0481; postoperative day 3: P ¼ .0172). IL-8 was
16.9  11.9 pg/mL in the landiolol group and 28.8 
26.6 pg/mL in the placebo group on returning to the ICU,
being significantly lower in the landiolol group (P¼ .0302).
Medical costs. The cost of landiolol treatment was
$413.76. The average cost of hospital treatment was
$35,679.48  $6273.40 in the landiolol group versus
$39,981.43  $13,417.62 in the placebo group, with the
cost being significantly lower in the landiolol group
(P ¼ .0202).Factors Related to Occurrence of Atrial Fibrillation
In regard to preoperative factors, there were significant
differences in age, euroSCORE, preoperative KL-6, landio-
lol use, hospital stay, and medical costs between patients
with and without Af (Table 3).
When risk factors for Af were investigated by univariate
analysis, significant factors were age 70 years or more,The Journal of Thoracic and CareuroSCORE of 10 or more, preoperative serum KL-6 300
U/mL or more, preoperative serum I-CTP 10 ng/mL or
more, preoperative non-use of angiotensin receptor
blockers (ARB), and non-use of landiolol. According to
multivariate analysis, significant factors were a euroSCORE
of 10 or more, preoperative non-use of ARB, and non-use of
landiolol (Table 4).DISCUSSION
In this study, we could reduce the incidence of postoper-
ative Af to 10% with the use of landiolol hydrochloride.
Previous studies using b-blockers or amiodarone have re-
ported significant reductions in postoperative Af compared
with placebo; however, the incidence varied widely from
3% to 34%.4,10,11 In the present study, the incidence of
postoperative Af was 10%, which was similar to the
values in previous reports. This b-blocker has strong anti-
ischemic and anti-inflammatory effects, as well as strong
sympathoinhibitory and cardiodepressant effects. However,
because our study did not make comparisons with other
drugs, this should be examined in future studies. In addition,
to reduce postoperative Af, studies using increased doses of
landiolol hydrochloride, longer treatment periods, or shift-
ing to oral b-blockers or antiarrhythmic drugs are needed.
Heart rates were significantly lower even after discontinu-
ing landiolol regardless of its 4-minute half-life. This
may be because myocardial protection through thediovascular Surgery c Volume 141, Number 6 1483
TABLE 3. Relation of various factors to postoperative atrial
fibrillation
Afþ Af – P value
No. 31 109
Age (y) 70.5  7.6 66.7  9.4 .0461
Gender 29:2 99:10 1.00
Body surface area (m2) 1.76  0.15 1.69  0.18 .0636
euroSCORE 7.2  3.7 5.4  3.3 .0068
Emergency surgery 11 25 .1584
Ejection fraction (%) 55.6  12.1 54.9  14.4 .8192
Risk factors
Diabetes mellitus 16 56 1.00
Hypertension 26 82 .4671
Hyperlipidemia 21 57 .1535
Obesity 8 19 .3091
Smoking 13 45 1.00
Cerebrovascular
disease
1 5 5
Chronic renal failure 5 19 1.00
Oral medications
ARB 11 65 .0240
ACE-I 2 8 1.0
Ca antagonist 15 37 .1480
Beta-blocker 11 31 .5072
Aldosterone blocker 3 6 .4147
Statin 12 33 .3901
hs-CRP (mg/dL) 0.74  1.1 0.68  1.5 .8534
IL-6 (pg/mL) 5.1  3.1 5.6  7.7 .8284
IL-8 (pg/mL) 6.4  4.1 6.0  3.9 .7307
Urinary OHdG
(ng/mg Cr)
11.2  5.2 11.4  5.8 .9350
KL-6 (U/mL) 299.1  108.0 207.5  99.0<.0001
I-CTP (ng/mL) 12.1  10.4 8.9  10.8 .1791
Hyaluronic acid (ng/mL) 58.0  53.0 45.0  41.8 .1427
Landiolol use 7 63 .0009
Oral medications
ARB 16 52 .8389
ACE-I 1 4 1.00
Ca antagonist 15 59 .6841
Beta-blocker 9 25 .4845
Aldosterone blocker 24 78 .6489
Statin 21 63 .4070
ACCT (min) 22.5  9.3 22.8  9.1 .1923
ECCT (min) 113.1  37.8 101.6  25.6 .1514
Hospital stay (d) 14.6  8.6 12.0  5.7 .0498
Hospital cost $35,679.48 
$6273.40
$39.981.43 
$13,417.62
.0109
Af, Atrial fibrillation; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-
converting enzyme inhibitor; hs-CRP, highly sensitive C-reactive protein; OHdG,
8-hydroxydeoxyguanosine; KL-6, sialylated carbohydrate antigen KL-6; I-CTP,
pyridinoline cross-linked telopeptide of type I collagen.
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effects of landiolol during the postoperative acute phase
also stabilized the heart rate after discontinuation.
Prophylactic administration of oral b-blockers has al-
ready been recommended for this purpose.12 Crystal and
colleagues19 performed a meta-analysis of 27 trials and1484 The Journal of Thoracic and Cardiovascular Surfound that postoperative Af occurred in 33% of the control
group versus 19% of the b-blocker group. They also per-
formed a meta-analysis of 8 trials of sotalol therapy and
found significantly less postoperative Af in the sotalol
group (17%) compared with the control group (37%).
There have already been some reports about the efficacy
of intravenous b-blockers, but few RCTs have been per-
formed. The chief reason is probably that traditional intra-
venous b-blockers can cause hypotension because of their
cardiodepressant effect.20,21
This study investigated landiolol hydrochloride, which
has a half-life of approximately 4 minutes (shorter than
that of conventional intravenous b-blockers16) and is un-
likely to cause hypotension because its b1/b2 selectivity ra-
tio is approximately 250:1 and it has little negative inotropic
effect.17,18 Sasao and colleagues18 reported that landiolol
caused a dose-dependent decrease of the heart rate in ani-
mals, but no change of mean blood pressure, whereas esmo-
lol decreased both the heart rate and the blood pressure.
In the present study, landiolol did not decrease the blood
pressure or cause cardiac failure, while having a marked
preventive effect on postoperative Af.
Various factors have been reported to show an association
with Af after cardiac surgery, including advanced age,
cardiac dysfunction, inflammation, ischemia–reperfusion
injury, oxidative stress, fibrosis, and sympathetic
hypertonia.1-9 This research indicated that landiolol has
anti-ischemic action, anti-inflammatory action, and sympa-
tholytic effects. In the present study, CPK-MB, troponin-I,
and heart fatty acid-binding protein were significantly lower
in the landiolol group, suggesting that prevention of ische-
mia might have reduced the occurrence of Af. Postoperative
tachycardia increases myocardial oxygen consumption and
causes myocardial ischemia by decreasing coronary artery
blood flow. Beta-blockers are said to decrease myocardial
oxygen consumption and prevent myocardial ischemia.22
Landiolol has not been adequately studied, but its anti-
ischemic effects were evident in animal experiments,23
and they were also clear from the results of this study.
It has been reported that production of IL-6 is inhibited
by b-blockers in patients with unstable angina.24 Invasion
due to cardiac surgery induces an increase in cytokines
and causes an intensive inflammatory response. This is con-
sidered to be strongly related to occurrence of Af. The pres-
ent study suggests that landiolol hydrochloride may be an
anti-inflammatory drug. Because postoperative increases
in IL-6 and IL-8 were limited in the study, it is highly likely
that the anti-inflammatory effect of landiolol hydrochloride
reduced the occurrence of Af. Lo and colleagues8 reported
that inflammation is related to postoperative Af and the in-
cidence of Af is higher in patients with a preoperative CRP
3.0 mg/dL or more. In the present study, only 6 patients had
a preoperative hs-CRP of 3.0 mg/dL or more, and preoper-
ative inflammation was unrelated to the occurrence of Af.gery c June 2011
TABLE 4. Risk factors for postoperative atrial fibrillation
Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Preoperative factors
Age>70 y 2.53 (1.11–5.73) .0266 2.44 (0.85–7.00) .0962
euroSCORE>10 points 8.153 (3.12–21.3) <.0001 7.10 (2.01–25.1) .0023
Ejection fraction>40% 0.70 (0.22–2.24) .5498
hs-CRP>3.0 mg/dL 0.57 (0.07–4.94) .6118
KL-6>300 U/mL 7.43 (1.43–38.8) .0174 1.45 (0.20–10.7) .7177
I-CTP>10 ng/mL 4.33 (1.16–16.3) .0298 1.79 (0.33–9.77) .5011
Hyaluronic acid>80 ng/mL 2.93 (0.80–10.7) .1034
ARB 0.37 (0.16–0.85) .0195 0.25 (0.08–0.76) .0142
ACE-I 0.87 n(0.18–4.33) .8656
Calcium antagonist 1.82 (0.81–4.09) .1149
Beta-blocker 1.38 (0.59–3.22) .4512
Aldosterone blocker 1.84 (0.43–7.82) .4093
Statin 1.46 (0.63–3.34) .3764
Intraoperative/postoperative factors
ACCT>40 min 2.81 (0.60–13.3) .1921
ECCT>120 min 2.12 (0.87–5.19) .1003
Landiolol 0.21 (0.09–0.54) .0010 0.22 (0.07–0.67) .0079
ARB 1.17 (0.53–2.60) .7011
ACE-I 0.88 (0.09–8.12) .9065
Calcium antagonist 0.79 (0.36–1.77) .5725
Beta-blocker 1.38 (0.56–3.36) .4860
Aldosterone blocker 0.78 (0.34–1.78) .5570
Statin 1.53 (0.66–3.57) .3206
CRP,C-reactive protein;KL-6, sialylated carbohydrate antigen KL-6; I-CTP, pyridinoline cross-linked telopeptide of type I collagen;ARB, angiotensin II receptor blocker; ACE-I,
angiotensin-converting enzyme inhibitor; ACCT, aortic crossclamping time; ECCT, extracorporeal circulation time.
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MPostoperative levels of IL-6, IL-8, and hs-CRP were signif-
icantly lower in the landiolol group, suggesting that the
anti-inflammatory effect of this drug might have reduced
the occurrence of Af.
This study investigated the risk factors for postoperative
Af by univariate and multivariate analyses. We found that
advanced age and high levels of fibrosis marker were risk
factors for Af, as previously reported, and determined that
preoperative ARB therapy was associated with a lower in-
cidence of postoperative Af. Preoperative oral treatment
with b-blockers, angiotensin-converting enzyme inhibitors
(ACE-I), and statins has been reported to decrease postop-
erative Af,5 but there has been little information about
ARB. Ozaydin and colleagues25 reported that preoperative
ACE-I therapy was associated with less frequent Af after
CABG. Guler and colleagues26 reported a significantly
higher angiotensin-II level on postoperative day 2 in pa-
tients with Af. Because angiotensin-II promotes electro-
physiologic and structural remodeling,26,27 postoperative
Af may be prevented by inhibiting angiotensin-II with
ACE-I or ARB therapy. We previously reported that low-
dose infusion of human atrial natriuretic peptide from the
start of cardiopulmonary bypass during cardiac surgery
improved the outcome28 and reduced the occurrence of
postoperative Af.29 Atrial natriuretic peptide inhibitsThe Journal of Thoracic and Carthe renin-angiotensin-aldosterone system28,30 and reduces
postoperative angiotensin-II levels, which might prevent
Af. Because ARB therapy also inhibits angiotensin-II, post-
operative Af could be decreased by preoperative ARB
administration in this manner, but further investigation is
needed.
This study also investigated the influence of Af on med-
ical costs. It has been reported that postoperative Af pro-
longs the hospital stay and increases costs. Mahoney and
colleagues31 reported that amiodaronewas effective for pre-
venting postoperative Af, particularly in elderly patients
and patients with complications. Gillespie and colleagues32
found that b-blocker prophylaxis shortened the hospital stay
by 2.2 days and decreased total hospital costs by 25.7%. In
this study, medical costs were significantly lower in the
landiolol group than in the placebo group. Although the
cost of landiolol in the landiolol group is approximately
$400, the average cost for the landiolol group was still sig-
nificantly lower than that for the placebo group. Because
drugs and longer hospital stays are required for Af treat-
ment, and the hospital stay of the placebo group was actu-
ally longer by approximately 3 days, these factors were
considered to increase the average cost. Oral drugs are
less expensive than injectable drugs; however, it has been
reported that intravenous administration reduces Af morediovascular Surgery c Volume 141, Number 6 1485
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Mthan oral administration,33 and intravenous administration
is more effective in reducing postoperative Af during the
acute postoperative phase of postoperative period.
This study was the first comparative study of the new
ultra–short-acting b-blocker landiolol hydrochloride com-
pound with placebo. In the future, the efficacy and problems
related to landiolol hydrochloride should be clarified in
comparative studies with amiodarone and other b-blockers
recommended in the American College of Cardiology/
American Heart Association guideline. Further study is
necessary.CONCLUSIONS
Postoperative Af was significantly less common in the
landiolol group compared with the placebo group (10%
vs 34.3%), and Af was reduced by intravenous landiolol
hydrochloride without causing hypotension or bradycardia.
It is possible that landiolol hydrochloride will eventually
become part of the regimen for perioperative management
of patients undergoing cardiac surgery.
The authors thank Hiroyuki Udagawa, Medical Processing Sec-
tion, Nihon University Itabashi Hospital, for extracting the health
cost data for this study.References
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